Comprehensive molecular characterization and identification of prognostic signature in stomach adenocarcinoma on the basis of energy-metabolism-related genes

Table 1 Clinical and pathologic characteristics of patients in the pre-processed The Cancer Genome Atlas and Gene Expression Omnibus stomach adenocarcinoma datasets

Characteristic	Training set (n = 170)	Validation set (n = 169)	P value	Entire TCGA dataset (n = 339)	GSE62254 dataset (n = 300)
Age (yr)			0.701
≤ 60	54	58		112	117
> 60	116	111		227	183
Progression-free survival			0.326
Absent	105	114		219	148
Present	65	55		120	152
Gender			0.238
Female	54	65		119	101
Male	116	104		220	199
Grade			0.278
G1	6	3		9	-
G2	63	60		123	-
G3	99	99		198	-
Gx	2	7		9	-
pT stage			0.614
T1	10	7		17	-
T2	38	35		73	-
T3	75	83		158	-
T4	50	41		91	-
pN stage			0.175
N0	52	46		98	-
N1	54	40		94	-
N2	30	38		68	-
N3/Nx	33	44		77	-
pM stage			0.707
M0	154	150		304	-
M1/Mx	16	19		35	-
Tumor Stage			0.11
Stage I	24	22		46	30
Stage II	57	49		106	96
Stage III	58	80		138	95
Stage IV	21	13		34	77
MSI status			0.793
MSI-H	21	19		40	68
MSI-L	18	16		34
MSS	65	71		136	186
EMT	-	-		-	46
Lauren classification			0.083
Diffuse	18	29		47	142
Intestinal	77	63		140	150
Mixed	6	10		16	8
WHO classification			0.057
Mucinous	6	8		14	-
Papillary	9	7		16	-
Poorly Cohesive	18	29		47	-
Tubular	59	37		96	-
Mixed	6	10		16	-

WHO: World Health Organization.